A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma
A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Inclusion Criteria
Exclusion Criteria